In real clinical practice, with the assistance of RAS inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists, finerenone safely and effectively reduces the urinary protein levels in DKD patients and ameliorates glomerular and tubular function, delaying disease progression. This evidence concerns the gene SLC5A2 and diabetic kidney disease.